Fortive (FTV) Q1 2026 earnings review
"New Fortive" Delivers Accelerating Core Growth and Robust Margin Expansion
Fortive's Q1 2026 results confirm the success of its post-spin transformation. Stripped of the cyclical Precision Technologies segment, the company delivered a highly predictable beat. Core revenue growth accelerated to 5.3% (though aided by a ~150 bps selling days tailwind), while aggressive share repurchases ($500M in Q1) propelled Adjusted EPS up 25.4% YoY to $0.70. Both the Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS) segments posted solid growth and margin expansion, proving the resilience of the 'Fortive Accelerated' strategy. With FY26 EPS guidance reaffirmed and trending toward the upper half ($2.90-$3.00), the company is executing flawlessly on its leaner, more focused mandate.
🐂 Bull Case
Adjusted EBITDA margins expanded by 140 bps YoY to 29.3%, driven by the Fortive Business System (FBS). AHS was the standout, expanding margins by 210 bps, shaking off the healthcare capex deferrals of 2025.
Fortive has deployed ~$1.8B into share repurchases over the last three quarters. This is actively translating mid-single-digit revenue growth into 25%+ EPS growth.
🐻 Bear Case
The impressive 5.3% core growth figure masks a ~150 basis point tailwind from extra selling days. True underlying organic growth is closer to 3.8%—solid, but less of an inflection point than the headline suggests.
While AHS margins are improving, the segment's GAAP operating margin remains a lackluster 10.0%, significantly trailing the IOS segment's 25.1%. True enterprise value unlock requires closing this structural gap.
⚖️ Verdict: 🟢
Bullish. Fortive is structurally leaner, growing faster organically, and actively using its strong free cash flow to shrink its share base. The 'Fortive Accelerated' strategy is working as advertised.
Key Themes
Advanced Healthcare Solutions (AHS) Rebound
AHS completely reversed its sluggish 2025 narrative, delivering 5.8% core growth and expanding adjusted EBITDA margins by 210 bps to 25.7%. This indicates that the US hospital capex deferrals that plagued the company in mid-2025 have thawed, and demand for equipment and consumables is normalizing.
Aggressive Capital Deployment Driving EPS
Management is leaning heavily into capital returns. The company completed another ~$500 million in share repurchases in Q1 (retaining ~9 million shares). Since launching the 'new Fortive' following the Ralliant spin-off, the company has bought back ~$1.8 billion in stock. This financial engineering is highly effective, turning 13.2% adjusted EBITDA growth into 25.4% adjusted EPS growth.
Software and SaaS Resilience
The Intelligent Operating Solutions (IOS) segment remains the steady engine of the enterprise, growing core revenue by 5.2% while maintaining elite 34.3% adjusted EBITDA margins. The continued mix shift toward recurring software revenues (like ServiceChannel and Provation AI tools) insulates the company from industrial cyclicality.
The Calendar Distortion
Management explicitly called out a ~150 basis point tailwind to revenue from extra selling days in Q1. If we strip this out, underlying core growth was ~3.8%. This is a deceleration from the 4% underlying IOS core growth reported in Q4 2025. Investors must adjust expectations for Q2 when this calendar benefit reverses.
Lingering Macro and Tariff Ghosts
While New Fortive is less cyclical than pre-spin Fortive, it is not immune to macro pressures. In 2025, the company highlighted significant tariff headwinds (estimated at $190-$220M gross impact) and European softness. The impressive Q1 margin expansion suggests FBS pricing countermeasures are working, but any degradation in pricing power could expose these underlying costs.
AHS Profitability Gap
Despite a strong quarter, Advanced Healthcare Solutions generated only $33M in GAAP operating profit on $326M in sales (10.0% margin). In contrast, IOS generated $186M in profit on $743M in sales (25.1% margin). The AHS segment still has a long way to go to pull its weight in the overall portfolio.
Other KPIs
Up 13.5% YoY from $171M in 25Q1. Strong cash conversion enables the company's aggressive buyback strategy without sacrificing balance sheet health.
Stable. Grew 8.0% YoY, roughly in line with revenue growth. Margins held steady at 34.3% (+10 bps). This segment is executing perfectly to plan as the cash cow of the business.
Guidance
Stable/Accelerating. Reaffirmed prior guidance, but management noted they are 'trending toward the upper half.' Taking the $2.95 midpoint against the $2.71 delivered in FY25, this implies healthy ~8.8% annual earnings growth, heavily supported by the reduced share count.
Key Questions
Underlying Demand Ex-Calendar
With the 150 bps selling-day tailwind removed, core growth looks closer to 3.8%. What is the organic core growth assumption for Q2 when the calendar effect normalizes?
AHS Margin Ceiling
AHS saw fantastic 210 bps margin expansion this quarter, but GAAP operating margins remain at 10%. What is the structural ceiling for AHS margins, and what specific FBS levers are left to close the gap with IOS?
M&A vs. Buybacks
With $1.8B deployed to buybacks over three quarters, the balance sheet is being actively optimized. Are you finding current software/SaaS valuations prohibitive for M&A, effectively forcing the capital allocation entirely toward repurchases?